- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer2007 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Apoferritin/vandetanib association is long-term stable but does not improve pharmacological properties of vandetanib2021 | Faculty of Science, Second Faculty of Medicine
- New possibilities of systemic treatment of thyroid cancer2018 | Publication without faculty affiliation
- Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation2019 | Faculty of Science, Second Faculty of Medicine
- Cytochrome P450 and flavin-containing monooxygenase enzymes are responsible for differential oxidation of the anti-thyroid-cancer drug vandetanib by human and rat hepatic microsomal systems2020 | Faculty of Science, Second Faculty of Medicine
- New possibilities of targeted therapy of thyroid cancer2017 | Publication without faculty affiliation
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer2007 | Faculty of Medicine in Pilsen
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer2007 | First Faculty of Medicine
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer2007 | Faculty of Physical Education and Sport
- Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro2018 | Faculty of Science
- Genetics of Thyroid Cancer and its Molecular Target Therapy2011 | Central Library of Charles University
- News in the treatment of thyroid cancer - view of an endocrinologist2020 | Second Faculty of Medicine
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer2023 | Publication without faculty affiliation